Cinacalcet + Placebo

Phase 3Completed

0 watching 0 views this week📈 Rising

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

Phase 3

Approved

Indication / Disease

Secondary Hyperparathyroidism

Conditions

Secondary Hyperparathyroidism, Chronic Kidney Disease

Trial Timeline

Aug 22, 2006 → Apr 10, 2012

NCT ID

NCT00345839

About Cinacalcet + Placebo

Cinacalcet + Placebo is a phase 3 stage product being developed by Amgen for Secondary Hyperparathyroidism. The current trial status is completed. This product is registered under clinical trial identifier NCT00345839. Target conditions include Secondary Hyperparathyroidism, Chronic Kidney Disease.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (6)

NCT ID	Phase	Status	Start	Completion	Indication
NCT01250405	Approved	Completed	May 1, 2012	Apr 1, 2014	Chronic Kidney Disease
NCT00975221	Phase 3	Completed	Mar 10, 2010	Dec 21, 2012	Hyperparathyroidism, Primary
NCT00975000	Phase 3	Completed	Dec 3, 2009	Apr 16, 2013	Chronic Allograft Nephropathy
NCT00345839	Phase 3	Completed	Aug 22, 2006	Apr 10, 2012	Secondary Hyperparathyroidism
NCT03776058	Phase 2	Completed	Jun 15, 2000	Dec 26, 2000	Primary Hyperparathyroidism
NCT03774771	Phase 2	Completed	Sep 29, 1998	Dec 13, 1999	Primary Hyperparathyroidism

Competing Products

20 competing products in Secondary Hyperparathyroidism

See all competitors

Product	Company	Stage	Hype Score
ASP7991 + Cinacalcet + Placebo	Astellas Pharma	Phase 2	52
Fycompa	Eisai	Pre-clinical	23
Fycompa	Eisai	Pre-clinical	23
KHK7580 + KRN1493	Kyowa Kirin	Phase 2/3	65
KHK7580	Kyowa Kirin	Phase 1	33
KHK7580	Kyowa Kirin	Phase 3	77
KHK7580	Kyowa Kirin	Phase 3	77
Cinacalcet HCl	Kyowa Kirin	Approved	85
KHK7580 + Cinacalcet Hydrochloride	Kyowa Kirin	Phase 3	77
Placebo + KHK7580 low dose + KHK7580 middle dose + KHK7580 high dose + KRN1493	Kyowa Kirin	Phase 2	52
dirucotide + Placebo	Eli Lilly	Phase 2/3	65
dirucotide	Eli Lilly	Phase 2/3	65
Paricalcitol + Calcitriol	AbbVie	Pre-clinical	23
paricalcitol + maxacalcitol + paricalcitol placebo + maxacalcitol placebo	AbbVie	Phase 3	77
Paricalcitol + Calcifediol	AbbVie	Approved	85
Paricalcitol + Darbepoetin alfa	AbbVie	Approved	85
Birabresib Dose 20 mg	Merck	Phase 1	33
Remibrutinib (blinded) + Placebo + Remibrutinib (Open label)	Novartis	Phase 3	77
Ranibizumab	Novartis	Approved	85
BAF312 + Baseline disease modifying therapies (DMTs) + BNT162 + mRNA-1273	Novartis	Approved	85

Other Products from Amgen